Brief: Jade Biosciences Announces First Cohort Dosed In Phase 1 Healthy Volunteer Clinical Trial Of Jade101, A Novel And Potentially Best-In-Class Anti-April Monoclonal Antibody Being Evaluated For The Treatment Of Iga Nephropathy
02/09/2025 13:28
Jade Biosciences Inc JBIO.O: JADE BIOSCIENCES ANNOUNCES FIRST COHORT DOSED IN PHASE 1 HEALTHY VOLUNTEER CLINICAL TRIAL OF JADE101, A NOVEL AND POTENTIALLY BEST-IN-CLASS ANTI-APRIL MONOCLONAL ANTIBODY BEING EVALUATED FOR THE TREATMENT OF IGA NEPHROPATHY JADE BIOSCIENCES: INTERIM, BIOMARKER-RICH PHASE 1 HEALTHY VOLUNTEER DATA ARE EXPECTED IN FIRST HALF OF 2026 Source text: ID:nGNX5xKFvz Further company coverage: JBIO.O
Recent news on Jade Biosciences
See all newsBrief: Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Jade Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Jade Biosciences Q2 net loss widens as costs rise
Brief: Jade Biosciences, Inc Q2 Cash & Investments USD 461.2 Million